Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Intraperitoneal and Systemic Chemotherapy in Advanced Gastric Cancer
NCT03061058Phase 3Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2013
- Primary completion
- Dec 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, Cisplatin micelle injection (HA132), oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, pemetrexed in gastric cancer (GC), peritoneal carcinomatosis (PC), sponsored by Nanjing Drum-Tower Hospital. Status: unknown.
02
Drugs
docetaxelCisplatin micelle injection (HA132)oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabpemetrexed
03
Conditions
gastric cancer (GC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT03061058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061058.